Danvatirsen clinical trials
Also written AZD9150 and ISIS 481464.
How each study uses danvatirsen is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the danvatirsen studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
12 studies that test it; most in 2018 (3)
| Year | Studies |
|---|---|
| 2012 | 1 |
| 2013 | 1 |
| 2015 | 2 |
| 2016 | 1 |
| 2017 | 2 |
| 2018 | 3 |
| 2023 | 1 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 9 · Other 3
AstraZeneca (6) · M.D. Anderson Cancer Center (1) · Acerta Pharma BV (1) · Ionis Pharmaceuticals, Inc. (1) · Montefiore Medical Center (1) · Flamingo Therapeutics NV (1) · National Cancer Institute (NCI) (1)
Often tested with
Tested in the same studies.
Ceralasertib (2) · AZD4547 (1) · Adavosertib (1) · Vistusertib (1) · Olaparib (1) · Oleclumab (1) · Trastuzumab deruxtecan (1) · Cediranib (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test danvatirsen.
- Jun 2027Danvatirsen Monotherapy Followed by Combination With Venetoclax in Relapsed/Refractory MDS & AMLPhase 1 · Montefiore Medical Center
Studies
Open first, then newest update. How each study uses danvatirsen is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 12
- Danvatirsen Monotherapy Followed by Combination With Venetoclax in Relapsed/Refractory MDS & AMLRecruitingPhase 1Montefiore Medical CenterNCT05986240Written as DanvatirsenHow we know
- Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder CancerActive, not recruitingPhase 1AstraZenecaNCT02546661Written as AZD9150How we know
- Study to Assess MEDI4736 With Either AZD9150 or AZD5069 in Advanced Solid Tumors & Relapsed Metastatic Squamous Cell Carcinoma of Head & NeckCompletedPhase 1/2AstraZenecaNCT02499328Written as AZD9150How we know
- Activity and Safety of Danvatirsen and Pembrolizumab in HNSCCTerminatedPhase 2Flamingo Therapeutics NVNCT05814666Written as DanvatirsenHow we know
- Phase II Umbrella Study of Novel Anti-cancer Agents in Participants With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing TherapyActive, not recruitingPhase 2AstraZenecaNCT03334617Written as DanvatirsenHow we know
- Danvatirsen and Durvalumab in Treating Patients With Advanced and Refractory Pancreatic, Non-Small Cell Lung Cancer, and Mismatch Repair Deficient Colorectal CancerActive, not recruitingPhase 2M.D. Anderson Cancer CenterNCT02983578Written as DanvatirsenHow we know
- AZD9150 Plus Durvalumab Alone or in Combination With Chemotherapy in Patients With Advanced, Solid Tumours and in Patients With Non-Small-Cell Lung CancerCompletedPhase 1AstraZenecaNCT03421353Written as AZD9150How we know
- Platform Study for the Treatment of Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma (PRISM Study)CompletedPhase 1Acerta Pharma BVNCT03527147Written as AZD9150How we know
- Study of AZD9150 and MEDI4736 (Durvalumab) in Japanese Adult Patients With Advanced Solid MalignanciesCompletedPhase 1AstraZenecaNCT03394144Written as AZD9150, DurvalumabHow we know
- Phase 1/2, Open-label, Dose-escalation Study of IONIS-STAT3Rx, Administered to Patients With Advanced CancersCompletedPhase 1/2Ionis Pharmaceuticals, Inc.NCT01563302Written as IONIS-STAT3RxHow we know
- AZD9150, a STAT3 Antisense Oligonucleotide, in People With Malignant AscitesTerminatedPhase 2National Cancer Institute (NCI)NCT02417753Written as AZD9150How we know
- A Phase I/Ib Study of AZD9150 (ISIS-STAT3Rx) in Patients With Advanced/Metastatic Hepatocellular CarcinomaCompletedPhase 1AstraZenecaNCT01839604Written as AZD9150How we know
Given beside what is tested · 3 — danvatirsen is usual care or a partner of the new treatment
- A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLCActive, not recruitingPhase 1AstraZenecaNCT03819465Written as DanvatirsenHow we know
- Neoadjuvant Durvalumab Alone or in Combination With Novel Agents in Resectable Non-Small Cell Lung CancerCompletedPhase 2MedImmune LLCNCT03794544Written as DanvatirsenHow we know
- MEDI4736 Alone and in Combination With Tremelimumab or AZD9150 in Adult Subjects With Relapsed/Refractory DLBCL (D4190C00023)CompletedPhase 1MedImmune LLCNCT02549651Written as AZD9150How we know
Codes
What other systems call danvatirsen · ClinicalTrials.gg INT000529
- MeSH (NLM) C000610954danvatirsenConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 31N550RD05DANVATIRSENConfirmed FDA, NLM
- NCI Thesaurus C101368DanvatirsenOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000610954 | danvatirsen | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 31N550RD05 | DANVATIRSEN | Confirmed FDA, NLM |
| NCI Thesaurus | C101368 | Danvatirsen | One source FDA |
Also registered as danvatirsen sodium (UNII S6A2UYH57V).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.